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Abstract
Precision medicine is modernizing strategies for clinical study design to help improve diagnoses guiding
individualized treatment based on genetic or phenotypic characteristics that discriminate between patients with
similar clinical presentations. Methodology to personalize treatment choices is being increasingly employed in clinical
trials, yielding favorable correlations with improved response rates and survival. In patients with diffuse large B-cell
lymphoma (DLBCL), disease characteristics and outcomes may vary widely, underscoring the importance of patient
classification through identification of sensitive prognostic features. The discovery of distinct DLBCL molecular
subtypes based on cell of origin (COO) is redefining the prognosis and treatment of this heterogeneous cancer. Owing
to significant molecular and clinical differences between activated B-cell-like (ABC)- and germinal center B-cell-like
(GCB)-DLBCL subtypes, COO identification offers opportunities to optimize treatment selection. Widespread adoption
of COO classification would greatly improve treatment and prognosis; however, limitations in interlaboratory
concordance between immunohistochemistry techniques, cost, and availability of gene expression profiling tools
undermine universal integration in the clinical setting. With advanced methodology to determine COO in a real-world
clinical setting, therapies targeted to specific subtypes are under development. The focus here is to review applications
of precision medicine exemplified by COO determination in DLBCL patients.
Introduction
Precision medicine is revolutionizing patient care by
reshaping drug development and improving diagnoses to
guide treatments. It is defined as individualized treatment
strategies based on the genetic or phenotypic character-
istics that discriminate between patients with similar
clinical presentations1. Cancer treatment has seen sig-
nificant diagnostic and therapeutic advances from the
increasing clinical implementation of personalized medi-
cine2. Individual molecular and genetic profiling have
augmented traditional cancer classification methods
leading to more effective treatment strategies. For exam-
ple, the use of molecular profiling has led to the devel-
opment of breakthrough therapies including trastuzumab
for HER2 positive breast cancer3 and vemurafenib for
BRAF V600E positive melanoma4,5.
Precision methods are increasingly employed in clinical
trials and have yielded favorable outcomes. A recent
meta-analysis of phase II clinical trials of single-agent
therapies across cancer types from 2010–2012 revealed
that personalized approaches significantly correlated with
improved response rates, progression free survival (PFS),
and overall survival (OS)6. Likewise, analysis of clinical
trials across cancer types that led to FDA drug approvals
between 1998 and 2013 revealed that use of personalized
approaches correlated with a higher relative response rate
ratio and longer PFS, with a trend toward prolonged OS7.
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These meta-analyses underscore the potential for
employment of precision medicine to guide cancer
treatment.
A relevant representation of precision medicine in B-
cell malignancies is the classification of diffuse large B-cell
lymphoma (DLBCL) based on cell of origin (COO). The
COO concept used to classify lymphoma defines every
lymphoid cancer by the most related non-malignant cell
type based on clinical, phenotypic, or genetic character-
istics8. Although more than 50% of DLBCL patients can
be cured by currently available chemoimmunotherapy
regimens, the clinical outcome of DLBCL is highly varied,
underscoring the importance of classification that can
lead to effective personalized treatment8. The focus of this
review is to summarize the current methods and clinical
applications of COO determination in DLBCL.
COO in diffuse large B-cell lymphoma
Importance of COO determination in DLBCL
Diffuse large B-cell lymphoma is a remarkably hetero-
geneous disease that comprises the majority of adult B-
cell lymphoma cases. Owing to this feature, prognosis
determination for patients with DLBCL was historically
difficult prior to the establishment of a durable classifi-
cation system. Patients responded initially to che-
motherapy but most were unable to achieve a sustainable
remission9. The introduction of the immunotherapy
rituximab into first-line treatment (generally combined
with CHOP) for DLBCL increased OS rates, however,
prognosis remains poor for patients with relapsed/
refractory (R/R) DLBCL10–12. Gene expression profiling
(GEP) of DLBCL using a specialized “Lymphochip”
microarray led to the identification of distinct molecular
subtypes based on COO, termed activated B-cell-like
(ABC) and germinal center B-cell-like (GCB) subtypes9.
Further efforts using GEP led to the discovery of a third
heterogeneous subtype of DLBCL, termed “type 3” or
“unclassifiable”, which does not express genes character-
istic of either ABC- or GCB-type cells13.
The discovery of the ABC and GCB subtypes provided a
basis for some of the observed heterogeneity of this dis-
ease. On a molecular level, both the ABC and GCB sub-
types overexpress the antiapoptotic protein BCL214.
However, ABC-type DLBCL is specifically associated with
constitutively active nuclear factor kappa B (NF-κB), often
via mutations in the B-cell receptor (BCR) signaling
pathway15. Clinically, the ABC subtype is associated with
worse outcomes; population-based studies report 5-year
OS rates of 35% for ABC-DLBCL patients and 60% for
GCB-DLBCL patients in the prerituximab era13 and 3-
year OS rates of ≈45% for ABC-DLBCL patients and ≈80%
for GCB-DLBCL patients following first-line R-CHOP
treatment16,17. Owing to the significant molecular and
clinical differences between ABC- and GCB-DLBCL
subtypes, COO identification offers opportunities to
optimize treatment selection per patient needs18. Several
targeted therapies are under investigation, including
proteasome inhibitors that reduce NF-κB signaling and
BCR pathway inhibitors for ABC-DLBCL18.
ABC- and GCB-DLBCL may also be associated with
additional molecular subsets that impact their clinical
relevance. Abnormalities in the MYC oncogene and BCL2
are associated with worse outcomes18–22. Double-
expressor lymphoma (DEL) occurs primarily in the ABC
subtype and is associated with high MYC and BCL2
expression. Alternatively, double-hit lymphoma (DHL;
with concurrent translocations of MYC and BCL2) is
primarily found in the GCB subtype18. DHL may be
prognostic for worse outcomes, however, a meta-analysis
of DLBCL studies found that translocations of MYC,
BCL2, or BCL6 in isolation most often reported a lack of
any significant prognostic information23. Single-hit MYC
rearrangement alone without evidence of BCL2 or BCL6
rearrangement has been associated with worse prognosis
compared with patients with normal MYC24,25. The 2016
NICE guidelines recommend that the presence of MYC,
BCL2, and BCL6 rearrangements should be interpreted in
the context of other prognostic factors26. Importantly,
despite the potential for MYC and BCL2 expression to be
considered as a prognostic biomarker, COO remains
independently associated with DLBCL outcomes with
prognostic significance21. While DHLs defined by MYC
and BCL2 genetic alterations are included in the updated
WHO classification system, MYC and BCL2 protein
alterations could be considered prognostic indicators
rather than a separate category19. These findings have
encouraged the use of COO identification in clinical
practice, which is increasingly available as a result of
advances in diagnostic methodology. In 2016, the WHO
classification of lymphoid neoplasms was revised to
include a requirement to determine COO at diagnosis for
patients with DLBCL19.
While the focus here is on advances in methodology to
differentiate key DLBCL subtypes based on COO, the field
continues to pursue more detailed examinations of
genetic and mutational signatures that drive disease pro-
gression, with the goal of informing the rational design of
single-agent and combination therapies27,28.
Methods of determination
Although widespread adoption of COO classification
would greatly improve treatment and prognosis, limita-
tions in the GEP method used to identify the ABC and
GCB subtypes prevented its integration in the clinical
setting. GEP using the original Lymphochip competitive
array or subsequent Affymetrix oligonucleotide micro-
array methods required considerable time and expense, as
well as fresh-frozen biopsy tissue, which prevented
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concurrent analysis of morphological features29,30. Several
practical alternatives to this technique are available,
including immunohistochemistry (IHC) staining and
novel GEP methods using formalin-fixed, paraffin-
embedded tissues (FFPE).
IHC offers several advantages for DLBCL COO deter-
mination over GEP. This method allows for direct
visualization of tumor samples, minimizing the possibility
for misclassification due to the presence of nontumor
tissue. Furthermore, protein levels are expected to cor-
relate better with outcome than messenger ribonucleic
acid expression31. However, the increased morphological
resolution of IHC comes at a price of decreased subtype
resolution, as this method can only distinguish the GCB
subtype from non-GCB (which includes both ABC and
unclassifiable subtypes). Moreover, the potential for high
inter- and intra-observer and laboratory variations hinder
reliable classification across laboratories32.
Effective IHC-based COO identification requires the
use of validated sets of protein markers. To this end,
several algorithms have emerged that show variable con-
cordance with GEP (Table 1). One of the earliest attempts
to classify DLBCL by IHC used markers of B-cell differ-
entiation, including CD10 and BCL6 for GCB expression
patterns and IRF4/MUM1 and CD138 expression pat-
terns, but did not predict clinical outcome33. Shortly
thereafter, the Hans algorithm emerged and became the
most commonly used method of IHC-based COO pre-
diction31. This method relies on expression of CD10,
BCL6, and IRF4/MUM1 to distinguish GCB from non-
GCB subtypes and has a 71% and 88% overall agreement
with GEP classification for the GCB and non-GCB sub-
types, respectively31. Though Hans algorithm con-
cordance with GEP is high, due to the prevalence of the
ABC subtype, the chances that the algorithm correctly
identifies an ABC subtype patient from a given sample are
proportionally lower, thus potentially limiting the ability
of IHC methods to retain the prognostic significance of
GEP34. Five-year OS rates between subtypes determined
by the Hans algorithm were somewhat comparable to
those found by GEP (OS rates: 76% GCB and 34% non-
GCB by Hans algorithm, 60% GCB and 35% ABC by
GEP)13,31. Additional proposed methods following the
establishment of the Hans algorithm included the Muris
Table 1 Immunohistochemistry algorithms for COO classification in DLBCL (shaded areas represent markers that are
included in each algorithm)
Algorithm 
Protein Expression Markers 
Comment 
CD
10
 
BC
L6
 
IR
F4
/M
U
M
1 
CD
13
8 
BC
L2
 
FO
XP
1 
GC
ET
1 
LM
O
2 
Colomo33      Not predicve of clinical outcome 
Hans31       Most commonly used algorithm 
Muris35     May misclassify some ABC39
Natkunam36  Low concordance with GEP39
Nyman37
Choi38
Tally39 Examined in any order; LMO2 examined for e score only 
Visco40
COO cell of origin, DLBCL diffuse large B-cell lymphoma
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algorithm, which assesses BCL2, CD10, and IRF4/MUM1
expression35, identification of LMO2 as a prognostic
marker by Natkunam et al.36, and Nyman et al.37 defining
the ABC subtype as having positive expression of either
IRF4/MUM1 or FOXP1. The Choi algorithm added
GCET1 and FOXP1 to the Hans algorithm to increase
accuracy and observed a 93% concordance with GEP, as
well as similar OS predictive power38. A key feature of the
IHC methods discussed thus far is that antibody staining
must proceed in a specific order, putting greater weight
for subtyping on the expression of some proteins over
others. The Tally algorithm proposed examining CD10
and GCET1 (positive GCB markers), and FOXP1 and
IRF4/MUM1 (positive ABC markers) in any order to
assign a score, using the GCB marker LM02 as a tie-
breaker39. The Tally method was associated with 93%
concordance with GEP in patients treated with R-CHOP.
Although the Tally and Choi methods showed higher
concordance with GEP than the Hans algorithm, technical
difficulties in performing IHC for GCET1, FOXP1, and
LM02 prevented their widespread adoption31,38,39. Lastly,
the Visco–Young algorithm attempted to address these
limitations by examining only three markers, CD10,
BCL6, and FOXP1, and was associated with 93% con-
cordance with GEP40.
While the ease of IHC-based methods for COO deter-
mination increases their clinical utility, success in pre-
dicting outcomes has been variable. This may be a general
limitation in the way the IHC algorithms were developed;
these methods were trained on retrospective population-
based cohorts of patients with DLBCL, while later analysis
examined cohorts of patients enrolled in clinical trials.
The Hans algorithm was designed for CHOP-treated
patients, and in the rituximab era was found to be less
prognostic for survival41–43. In multiple analyses, includ-
ing retrospective analysis of the RICOVER-60 trial
involving 949 patients, the Hans algorithm was predictive
of OS in CHOP-treated, but not R-CHOP-treated
patients41,42. This phenomenon is not exclusive to the
Hans algorithm. In a study containing 157 patients treated
with rituximab-containing chemoimmunotherapy, the
proportion of misclassification rates for IHC compared
with GEP according to the Colomo, Hans, Muris, Choi,
and Tally algorithms were 41%, 48%, 30%, 60%, and 40%,
respectively. Moreover, while GEP predicted GCB and
ABC classifications with 5-year OS rates of 80% and 45%,
respectively, none of the IHC methods predicted OS dif-
ferences between GCB and non-GCB subgroups44.
Nonetheless, in a study of 475 patients treated with R-
CHOP, the Visco–Young algorithm resulted in high
concordance with GEP (93%) and strong prognostic
power that matched GEP40. Further confounding this
methodology, in the R/R setting, the Hans algorithm did
not predict outcome in patients receiving ifosfamide,
carboplatin, and etoposide (ICE)45; however, COO
determined by the Hans algorithm in patients receiving
rituximab plus ICE (R-ICE) or rituximab plus dex-
amethasone, high-dose cytarabine, and cisplatin (R-
DHAP) in the CORAL study predicted a favorable
response for GCB patients to R-DHAP46. Furthermore,
there is some evidence that these methods are not clas-
sifying overlapping patient sets; an analysis comparing
different IHC algorithms showed that only 4% of patients
were classified as GCB and 21% as non-GCB by all 9 IHC
methods tested47. These results indicate that IHC tech-
niques to assess COO in DLBCL require additional
refinement in the rituximab era, though IHC may be
useful for certain DLBCL subtypes that remain challen-
ging to identify, such as T-cell/histiocyte-rich large B-cell
lymphoma48.
While the limitations of initial efforts to classify DLBCL
tumors by COO using cDNA Lymphochip microarrays on
flash-frozen tissue samples prevented their use for clinical
purposes, advances in GEP technology over the past
decade have reignited the development of new expression
profiling techniques to assess COO (Table 2)9,49,50.
Within three years of the initial establishment of COO
subtypes by Alizadeh et al.9, a microarray platform-
Table 2 Comparison of methods for COO determination in DLBCL
Method Manufacturer Number of genes Accuracy versus gold standard Useful in FFPET Interlab reproducibility Expense
IHC Various 1–10 ++ +++ + ++
Multiplex RT-PCR Primera Dx 1–20 ++ +++ Not tested ++
qNPA HTG-molecular 1–48 ++ +++ Not tested ++
Digital array Nanostring 10–100s +++ +++ +++ ++
Oligonucleotide array Affymetrix 1000s +++ ++ Not tested +++
DASL Illumina 1000s Not tested +++ Not tested +++
Reprinted from Rimsza et al.50, with permission from AACR
+ low; ++ moderate; +++, high
DASL cDNA-mediated annealing, selection, extension, and ligation, FFPET fresh-frozen paraffin-embedded tissue, IHC immunohistochemistry, qNPA quantitative
nuclease protection assay, RT-PCR real-time polymerase chain reaction
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independent method of assigning subtype using a Baye-
sian predictor based on the expression over 27 key genes
was developed30. A significant hurdle in the use of GEP to
determine COO subtypes was adequate storage and pro-
cessing of flash-frozen tissue samples. Accordingly, sev-
eral methods were developed for use on FFPE sections. A
quantitative nuclease protection assay for the expression
of 12 genes that correlated significantly with COO sub-
type and can be applied to FFPE sections has been
reported, but not widely implemented due to the
requirement of an array with limited availability51. Sub-
sequently, a method using the commercial Illumina
platform and an algorithm identified by a DLBCL auto-
matic classifier (DAC) correctly classified FFPE samples
with a significant relationship between subtype and sur-
vival in 172 patients treated with first-line R-CHOP52.
However, this platform has subsequently been dis-
continued. Based on the DAC and 20 of 27 previously-
identified key genes30, a robust, platform-independent,
subtype classifier using either fresh frozen or FFPE tissue
was developed that is potentially suitable for clinical use
on individual patients. Subsequently, a method was
developed to probe RNA using Affymetrix technology on
FFPE samples that enabled accurate disease classification
with microarrays53. Using this classifier, comparative
analysis across 10 DLBCL data sets, including 2030
patients, showed a superior separation of survival out-
comes based on COO rather than other classifiers54.
Despite its complexity compared with IHC, GEP remains
a precise and valuable method for COO prediction.
The current standard for predicting COO from GEP
utilizes the commercially available NanoString® nCoun-
ter® Analysis System (NanoString Technologies, Seattle,
WA, USA). The Lymph2Cx assay was developed as an
economical, robust, and molecularly validated method to
determine COO using GEP on FFPE tissue55. Examina-
tion of 93 genes previously reported to differentiate
between subtypes16 using the NanoString® nCounter®
Analysis System led to the identification of 20 key genes.
Validation of the Lymph2Cx method in an independent
cohort found a 2% error rate in COO assignment com-
pared with 9%, 6%, and 17% error rates for the Hans,
Tally, and Choi IHC algorithms, respectively31,38,39,55.
Survival outcomes were similar to those obtained by the
gold standard GEP technique by Lenz et al.16 (Fig. 1).
Importantly, concordance between two independent
laboratories employing this technique was greater than
95%55. Subsequent analyses using the Lymph2Cx assay
examined a cohort of 344 patients with de novo DLBCL
treated with R-CHOP and showed that no misclassifica-
tions were observed21. This method recapitulated prog-
nostic predictions independently of International
Prognostic Index score, with patients classified to the
ABC subgroup having significantly inferior time to
progression, PFS, disease-specific survival, and OS21. In
addition, COO (GCB versus ABC) predicted by the
Lymph2Cx assay remained prognostically-relevant inde-
pendent of BCL2 and MYC protein expression status,
albeit with BCL2/MYC co-expression allowing for iden-
tification of patients with poor prognosis in both COO
subtypes21,56. The CALYM research consortium has
reported a reverse transcriptase multiplex ligation-
dependent probe amplification method which achieves
85% correct classification and requires only standard
laboratory equipment57.
Currently, methods using the NanoString® nCounter®
Analysis System are being employed to assess COO in
DLBCL in clinical trials. NanoString technology was used
for COO subtype identification in a subset of patients (n
= 47) from the phase Ib/II REAL07 study, which is eval-
uating lenalidomide plus R-CHOP in elderly patients with
DLBCL58. An analysis of concordance between the
NanoString method and IHC using the Hans algorithm
demonstrated a 6% rate of misclassification, thus
demonstrating that this method was feasible for use in
COO assignment in the context of a prospective clinical
trial58. The Lymph2Cx assay is being used in real-time as
a companion diagnostic in the randomized, phase III
ROBUST (NCT02286062) trial testing lenalidomide/R-
CHOP (R2-CHOP) versus placebo/R-CHOP in previously
untreated ABC-DLBCL patients59. Preliminary evaluation
of COO in an ongoing study identified ABC subtype in
33% of the patients screened, with a mean turnaround
time for subtype identification of 2.25 days60,61. The use of
the NanoString® nCounter® Analysis System has also
begun to provide COO data in R/R DLBCL. A second
method using this system was recently developed using
145 differentially expressed genes assessed in fresh frozen
and FFPE biopsy samples from 18 patients with R/R
DLBCL in a phase IIb fostamatinib trial50,62. Results were
in close agreement with those reported for Lymph2Cx
and 88% concordant with biopsies taken at initial diag-
nosis, suggesting COO stability through treatment and
relapse. This level of concordance is similar to what had
been reported in an analysis of the Lymph2Cx assay and
the Hans algorithm in patients treated with R-CHOP63.
Thus, GEP techniques are now sophisticated enough to be
utilized in real-time for COO classification in a pro-
spective clinical study to provide valuable data for patients
with DLBCL.
Clinical outcomes based on DLBCL subtype
With the increased availability of methods to determine
COO in a real-world clinical setting, therapies targeted to
specific subtypes are under development. For example,
the constitutive activity of NF-κB in the ABC subtype has
increased interest in agents targeting this pathway64.
Bortezomib, ibrutinib, and lenalidomide affect NF-κB
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activation through different mechanisms and are under
investigation in ABC-DLBCL64–66. Despite the success of
rituximab, 40% of patients still fail first-line treatment and
develop relapsed disease, and most will eventually suc-
cumb to their disease18. Thus, treatment strategies
focusing on COO in the first-line and relapsed setting are
valuable for DLBCL treatment.
Role of COO in the first-line setting
In the first-line setting, multiple agents have been
reported to improve the unfavorable outcomes associated
with ABC-DLBCL by targeting overactive NF-κB signal-
ing. Bortezomib is a proteasome inhibitor that prevents
degradation of the NF-κB inhibitor IκBα64. Non-GCB
patients treated with bortezomib plus R-CHOP experi-
enced similar PFS and OS as GCB patients (COO deter-
mined by the Hans algorithm)67. The Bruton tyrosine
kinase (BTK) inhibitor ibrutinib interferes with BCR
signaling and downstream NF-κB activation65. In a phase
Ib study of ibrutinib plus R-CHOP, all four non-GCB-
DLBCL patients (identified by the Hans algorithm) who
received any dose of ibrutinib achieved complete
responses (CR)68. A randomized phase III study of ibru-
tinib in non-GCB-DLBCL patients has been initiated
based on these results (NCT01855750). Lenalidomide is
an immunomodulatory agent that downregulates IRF4/
MUM1 and subsequently decreases BCR-dependent NF-
κB activity in ABC-DLBCL cells in vitro and in tumor
xenograft models66. A phase I trial established lenalido-
mide’s tolerability when administered with R-CHOP, and
the combination resulted in a 100% overall response rate
(ORR) in DLBCL patients69. Subsequently, lenalidomide
was tested in two phase II studies in combination with R-
CHOP (i.e., R2-CHOP) in patients classified by COO
using the Hans algorithm70,71. One study of 60 DLBCL
patients receiving R2-CHOP showed similar 2-year OS
Fig. 1 Outcomes by COO in an independent validation cohort of 68 patients receiving first-line CHOP or R-CHOP. a PFS by COO per
Lymph2Cx, b OS by COO group per Lymph2Cx, c PFS by COO group per gold standard GEP, and d OS by COO per gold standard GEP. CHOP,
cyclophosphamide, doxorubicin, vincristine, prednisone; COO cell of origin, GEP gene expression profiling, OS overall survival, PFS progression-free
survival, R-CHOP rituximab with CHOP, RR relative risk (with 95% confidence interval). Republished with permission of Blood: a journal of the
American Society of Hematology, from Scott et al.55; permission conveyed through Copyright Clearance Center, Inc
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rates for GCB and non-GCB patients (75% and 83%,
respectively) compared with historical controls receiving
R-CHOP (no lenalidomide), where 2-year OS was sig-
nificantly different in GCB and non-GCB patients (78%
and 46%, respectively)70. The phase II REAL07 study
reported similar results of 2-year PFS (71% versus 81%)
and OS (88% versus 94%) rates in patients with GCB and
non-GCB subtypes treated with R2-CHOP71. Overall,
these studies reflect the potential impact of targeting
molecular pathways based on COO specificity and the
potential utility of COO determination to guide treatment
choices.
Role of COO in the relapsed setting
The prognostic significance of COO in relapsed DLBCL
is less certain than in the first-line setting, as data evalu-
ating COO in this population are more limited72. It is
expected that there may be an increased presence of ABC/
non-GCB subtypes in relapsed DLBCL due to previous
studies showing worse responses for these patients to
first-line therapy45. The role of COO in predicting sur-
vival following relapse has been investigated, although
data were available in a limited number of patients. Of 985
patients who initially received anthracycline-based che-
moimmunotherapy, 128 had available COO data at
relapse. Of these patients, 59% had GCB and 41% had
non-GCB DLBCL as defined by the Hans algorithm,
directly refuting the idea that ABC/non-GCB patients are
overrepresented in relapsed DLBCL, and no difference in
OS was found between GCB and non-GCB patients73.
Theoretically, it is not surprising that there are differences
between lines of therapy, as first-line treatments may
impact the balance or presence of certain COO subtypes
in patients, with more aggressive phenotypes remaining
following therapy.
The prognostic power of COO subtype analysis in R/R
DLBCL patients appears to vary by treatment. The ran-
domized phase III CORAL study compared R-ICE and R-
DHAP regimens in patients in first relapse or who were
refractory after first-line therapy74. Upon further analysis,
it became evident that patients with the GCB subtype
determined by the Hans algorithm had significantly
improved responses to R-DHAP, while subtype was not
predictive of response to R-ICE46. Thus, there is a clear,
careful consideration of treatment combinations when
evaluating the potential impact of COO subtype in
DLBCL patients.
Therapies targeting overactive NF-κB signaling are
being investigated in relapsed DLBCL, although pre-
liminary results have been variable. A phase I study
evaluated bortezomib combined with chemotherapy in 31
patients with R/R DLBCL who received a median of two
prior therapies; patients were grouped by COO which was
determined by IHC and GEP. Results of this study showed
that bortezomib combined with chemotherapy provided a
significantly higher ORR and OS in patients with the ABC
subtype, with very little benefit derived by GCB patients75.
The BTK inhibitor ibrutinib was evaluated in patients
with DLBCL on the basis that activating mutations of the
BCR pathway activate NF-κB via BTK76. A phase I/II trial
examined single-agent ibrutinib in 80 patients with R/R
DLBCL in which COO subtype was determined by GEP.
Patients with the ABC subtype responded better to ibru-
tinib therapy, with median OS of 10.3 and 3.4 months and
ORR of 37% (16% CR) and 5% (0% CR) in the ABC and
GCB subtypes, respectively76. On the basis of these
results, the phase III PHOENIX study (NCT01855750)
evaluated the addition of ibrutinib to R-CHOP for
patients with newly diagnosed non-GCB DLBCL. This
study did not meet its primary endpoint of event-free
survival, although subtype analysis is ongoing77.
Lastly, multiple studies have shown the benefits of
lenalidomide treatment to patients with relapsed, non-
GCB DLBCL. A retrospective analysis of 40 R/R DLBCL
patients treated with salvage lenalidomide reported sig-
nificantly higher ORR (53% versus 9%) and longer PFS
(6.2 versus 1.7 months) in patients with the non-GCB
compared with the GCB subtype determined by IHC
using the Hans algorithm78. Subsequently, the DLC-001
phase II/III study of 102 patients with stem cell trans-
plantation-ineligible, R/R DLBCL who received single-
agent lenalidomide or investigator’s choice (IC, gemcita-
bine, rituximab, etoposide, or oxaliplatin) found that
lenalidomide significantly improved PFS (13.6 weeks
lenalidomide versus 7.9 weeks IC; P= 0.04) and numeri-
cally improved ORR (28 versus 12%; P= 0.08) and median
OS (31 versus 24.6 weeks; P= 0.67)79. Importantly,
median PFS for lenalidomide versus IC, respectively, was
more improved in non-GCB subtypes (15.1 versus
7.1 weeks; P= 0.02) compared with GCB subtypes (10.1
versus 9.0 weeks; P= 0.55) determined by IHC. When
COO was stratified by GEP, through an exploratory
assessment, the clinical outcome was more pronounced in
ABC-type patients, but did not reach clinical significance.
When lenalidomide was combined with R-ICE (RICER) in
a phase I/II study, no dose-limiting toxicity was encoun-
tered and response rates were favorable (60% CR and
13% PR)80. COO subtype was determined by IHC, and
ORRs were 100% and 60% for GCB and non-GCB
patients, respectively. Responding patients received
autologous stem cell transplantation (ASCT) followed by
lenalidomide maintenance. Few relapses occurred fol-
lowing ASCT, however, all were of the GCB subtype. At
present, very few trials are testing the effect of targeted
therapies in DEL/DHL patients. A phase II trial is cur-
rently recruiting post-stem cell transplant DHL patients
to assess ibrutinib (NCT02272686). Overall, studies in the
relapsed setting indicate that newer therapies for DLBCL
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are effective and provide a rationale for the increased
investigation of the applicability and integration of COO
classification.
Discussion
The discovery of divergent COO subtypes provides a
basis for gaining increasing knowledge about the clinical
heterogeneity of DLBCL at a molecular level. In a real-
world application of precision medicine, COO determi-
nation at diagnosis advises physicians on anticipated
patient prognosis and is increasingly used to inform
selection of therapy. The method used to determine COO
is an important consideration, as methods based on IHC
have a higher rate of misclassification versus GEP. From a
retrospective perspective, misclassifications have few
consequences, however, when being used to guide first-
line treatment, the cost of misclassification can be sig-
nificant. Thus, it is essential to continue to refine and
cross-validate the methods used to determine COO
clinically. Nonetheless, the ability to perform real-time
COO classification has encouraged the continued eva-
luation of molecular-based agents including bortezomib,
ibrutinib, and lenalidomide, alone or in combination, to
improve the dismal prognosis for patients with higher risk
DLBCL. Although promising, evidence to date is limited,
particularly in the R/R setting. As ongoing and planned
studies increasingly make use of GEP assays as companion
diagnostics, evidence-based fine-tuning of therapies based
on COO and additional pathobiological factors will help
lay the groundwork for providing improved clinical ben-
efit to patients with this aggressive disease.
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